1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWTH IN GERIATRIC POPULATION
3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF THERAPY
3.2.2. HIGH RISK OF SIDE EFFECTS

4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
4.6.1. SOURCE
4.6.2. APPLICATION
4.6.3. EPITOPE
4.6.4. VALIDATION
4.7. REGULATORY FRAMEWORK

5. MARKET BY PRODUCT
5.1. IGG
5.2. IGA
5.3. IGM
5.4. IGE
5.5. IGD

6. MARKET BY MODE OF DELIVERY
6.1. INTRAVENOUS IMMUNOGLOBULIN
6.2. SUBCUTANEOUS IMMUNOGLOBULIN
6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7. MARKET BY APPLICATION
7.1. HYPOGAMMA GLOBULINEMIA
7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
7.3. PRIMARY IMMUNODEFICIENCY DISEASES
7.4. MYASTHENIA GRAVIS
7.5. MULTIFOCAL MOTOR NEUROPATHY
7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
7.7. INFLAMMATORY MYOPATHIES
7.8. SPECIFIC ANTIBODY DEFICIENCY
7.9. GUILLAIN-BARRE SYNDROME
7.10. OTHER APPLICATIONS

8. MARKET BY DISTRIBUTION CHANNEL
8.1. HOSPITAL PHARMACY
8.2. SPECIALTY PHARMACY
8.3. OTHER DISTRIBUTION CHANNELS

9. MARKET BY END-USER
9.1. HOSPITALS & CLINICS
9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. KEY GROWTH ENABLERS
10.1.3. KEY CHALLENGES
10.1.4. KEY PLAYERS
10.1.5. COUNTRY ANALYSIS
10.1.5.1. UNITED STATES
10.1.5.2. CANADA
10.2. EUROPE
10.2.1. MARKET SIZE & ESTIMATES
10.2.2. KEY GROWTH ENABLERS
10.2.3. KEY CHALLENGES
10.2.4. KEY PLAYERS
10.2.5. COUNTRY ANALYSIS
10.2.5.1. UNITED KINGDOM
10.2.5.2. GERMANY
10.2.5.3. FRANCE
10.2.5.4. SPAIN
10.2.5.5. ITALY
10.2.5.6. NORDIC COUNTRIES
10.2.5.7. REST OF EUROPE
10.3. ASIA-PACIFIC
10.3.1. MARKET SIZE & ESTIMATES
10.3.2. KEY GROWTH ENABLERS
10.3.3. KEY CHALLENGES
10.3.4. KEY PLAYERS
10.3.5. COUNTRY ANALYSIS
10.3.5.1. CHINA
10.3.5.2. JAPAN
10.3.5.3. INDIA
10.3.5.4. SOUTH KOREA
10.3.5.5. INDONESIA
10.3.5.6. THAILAND
10.3.5.7. VIETNAM
10.3.5.8. AUSTRALIA
10.3.5.9. REST OF ASIA-PACIFIC
10.4. REST OF WORLD
10.4.1. MARKET SIZE & ESTIMATES
10.4.2. KEY GROWTH ENABLERS
10.4.3. KEY CHALLENGES
10.4.4. KEY PLAYERS
10.4.5. REGIONAL ANALYSIS
10.4.5.1. LATIN AMERICA
10.4.5.2. MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGERS & ACQUISITIONS
11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
11.1.3. PARTNERSHIPS & AGREEMENTS
11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
11.2. COMPANY PROFILES
11.2.1. ADMA BIOLOGICS
11.2.2. BIO PRODUCTS LABORATORY
11.2.3. BIOTEST AG
11.2.4. CHINA BIOLOGIC PRODUCTS INC
11.2.5. CSL BEHRING
11.2.6. GRIFOLS SA
11.2.7. KAMADA LTD
11.2.8. KEDRION BIOPHARMA
11.2.9. LFB GROUP
11.2.10. OCTAPHARMA AG
11.2.11. PFIZER INC
11.2.12. SANQUIN PLASMA PRODUCTS BV
11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD
11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED